Recurrent retroperitoneal sarcoma: beyond resectability toward a biology-based therapeutic framework

Area of Science:

• Oncology
• Surgical Oncology
• Translational Research

Background:

• Recurrent retroperitoneal sarcoma (RPS) presents a substantial therapeutic challenge.
• Recurrence signifies diverse tumor biology, impacting local and systemic management strategies.
• Current management often lacks a nuanced, biology-driven framework for recurrent disease.

Purpose of the Study:

• To propose a biology-based framework for managing recurrent RPS.
• To integrate key factors like histology, disease-free interval, and tumor kinetics into treatment decisions.
• To guide personalized surveillance and therapeutic proportionality for recurrent RPS.

Main Methods:

• Review of current literature on retroperitoneal sarcoma recurrence.
• Development of a framework incorporating tumor histology, disease-free interval, growth kinetics, multifocality, resectability, and functional reserve.
• Analysis of the roles of surgery, radiotherapy, and systemic therapy in recurrent RPS.

Main Results:

• Histological subtype significantly impacts recurrence patterns (e.g., liposarcoma vs. leiomyosarcoma).
• Disease-free interval and tumor growth rate are critical dynamic prognostic indicators.
• Complete resection is vital, but resectability alone does not guarantee surgical benefit; therapeutic proportionality is key.

Conclusions:

• A biology-based framework enhances the management of recurrent RPS.
• Integrating dynamic tumor behavior factors improves prognostic accuracy and treatment timing.
• Future advancements require biomarkers, predictive models, and personalized approaches for recurrent RPS.